NZ597222A - Substituted 8-[6-Amino-3-Pyridyl]Xanthines - Google Patents

Substituted 8-[6-Amino-3-Pyridyl]Xanthines

Info

Publication number
NZ597222A
NZ597222A NZ597222A NZ59722207A NZ597222A NZ 597222 A NZ597222 A NZ 597222A NZ 597222 A NZ597222 A NZ 597222A NZ 59722207 A NZ59722207 A NZ 59722207A NZ 597222 A NZ597222 A NZ 597222A
Authority
NZ
New Zealand
Prior art keywords
pyridyl
propyl
cyclopropyl
amino
xanthine
Prior art date
Application number
NZ597222A
Other languages
English (en)
Inventor
Guoquan Wang
Robert D Thompson
Jayson M Rieger
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of NZ597222A publication Critical patent/NZ597222A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ597222A 2006-06-16 2007-06-13 Substituted 8-[6-Amino-3-Pyridyl]Xanthines NZ597222A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US80556406P 2006-06-22 2006-06-22
US11/811,823 US7884100B2 (en) 2006-06-16 2007-06-12 Substituted 8-[6-amino-3-pyridyl]xanthines

Publications (1)

Publication Number Publication Date
NZ597222A true NZ597222A (en) 2013-06-28

Family

ID=56290980

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597222A NZ597222A (en) 2006-06-16 2007-06-13 Substituted 8-[6-Amino-3-Pyridyl]Xanthines

Country Status (18)

Country Link
US (2) US7884100B2 (OSRAM)
EP (1) EP2029143B1 (OSRAM)
JP (1) JP5417558B2 (OSRAM)
KR (1) KR101413404B1 (OSRAM)
CN (1) CN103145712A (OSRAM)
AU (1) AU2007261568B2 (OSRAM)
BR (1) BRPI0712001B8 (OSRAM)
CA (1) CA2655598C (OSRAM)
DK (1) DK2029143T3 (OSRAM)
EA (1) EA016791B1 (OSRAM)
ES (1) ES2548437T3 (OSRAM)
HU (1) HUE026457T2 (OSRAM)
IL (1) IL195916A (OSRAM)
MX (1) MX2008015954A (OSRAM)
MY (1) MY152178A (OSRAM)
NZ (1) NZ597222A (OSRAM)
PL (1) PL2029143T3 (OSRAM)
PT (1) PT2029143E (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PT1658291E (pt) * 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
JP2024521704A (ja) 2021-05-18 2024-06-04 アドベイト，エルエルシー Ａ２ｂアンタゴニストとしての環状アミド含有ピリジルキサンチン

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1255550A2 (en) * 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
HU229504B1 (hu) 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
PT1658291E (pt) 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
ES2387653T3 (es) 2004-09-01 2012-09-27 Gilead Sciences, Inc. Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B
US20060053029A1 (en) 2004-09-03 2006-03-09 Butler Keith R Methods and systems for providing an enterprise supply management portal
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
CN101198608B (zh) 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
RU2457842C2 (ru) * 2006-03-17 2012-08-10 Гайлид Пало Альто, Инк. Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
CA2652858A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina

Also Published As

Publication number Publication date
PL2029143T3 (pl) 2015-12-31
US8258142B2 (en) 2012-09-04
US20080004292A1 (en) 2008-01-03
AU2007261568A1 (en) 2007-12-27
EP2029143A2 (en) 2009-03-04
JP2010500284A (ja) 2010-01-07
AU2007261568B2 (en) 2013-05-16
PT2029143E (pt) 2015-10-20
CA2655598A1 (en) 2007-12-27
MY152178A (en) 2014-08-15
EP2029143B1 (en) 2015-07-08
ES2548437T3 (es) 2015-10-16
IL195916A0 (en) 2009-09-01
CN103145712A (zh) 2013-06-12
IL195916A (en) 2015-06-30
BRPI0712001A2 (pt) 2012-01-10
EA200900010A1 (ru) 2009-10-30
HUE026457T2 (en) 2016-05-30
KR20090029268A (ko) 2009-03-20
BRPI0712001B8 (pt) 2021-05-25
BRPI0712001B1 (pt) 2020-04-07
CA2655598C (en) 2014-10-28
US20110082139A1 (en) 2011-04-07
JP5417558B2 (ja) 2014-02-19
DK2029143T3 (en) 2015-09-21
MX2008015954A (es) 2009-03-06
US7884100B2 (en) 2011-02-08
EP2029143A4 (en) 2009-07-15
KR101413404B1 (ko) 2014-06-27
EA016791B1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
NZ597222A (en) Substituted 8-[6-Amino-3-Pyridyl]Xanthines
EP1722798B1 (en) Pyrimidine compounds as purine receptor antagonists
ES2382154T3 (es) Derivados de triazolo [4,5-D]piramidina y su uso como antagonistas de los receptores de purina
JP5918693B2 (ja) Ｅｇｆｒ阻害剤及び疾患の治療方法
TW200728299A (en) New pyrazine derivatives
Miwa et al. Discovery of 1-{4-[1-(2, 6-difluorobenzyl)-5-[(dimethylamino) methyl]-3-(6-methoxypyridazin-3-yl)-2, 4-dioxo-1, 2, 3, 4-tetrahydrothieno [2, 3-d] pyrimidin-6-yl] phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor
JP4179879B2 (ja) Ｎ−置換非アリール系複素環ｎｍｄａ／ｎｒ２ｂ拮抗薬
Vu et al. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists
EP3184527A1 (en) 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
CN109843858A (zh) 某些化学实体、组合物及方法
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
NO20081211L (no) Xantinderivater som selektive HM74A agonister
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
TWI631117B (zh) 吲哚啉－２－酮衍生物
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
JP5667085B2 (ja) Ａｋｔインヒビターとしての融合されたピリミジン
RS53489B1 (sr) Jedinjenja i preparati protein kinaznih inhibitora
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
EA021410B1 (ru) Новое производное фенилимидазола в качестве ингибитора фермента pde10a, фармацевтическая композиция на его основе и его применение для лечения нейродегенеративных и психиатрических расстройств
SG191103A1 (en) Pyrazole derivative
BG107999A (en) Imidazolyl derivatives as corticotropin releasing factor inhibitors
Vidal et al. Discovery and characterization of 4 ‘-(2-Furyl)-N-pyridin-3-yl-4, 5 ‘-bipyrimidin-2 ‘-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist
Wei et al. Identification of new potent A1 adenosine receptor antagonists using a multistage virtual screening approach
CN104961732A (zh) 作为crth2拮抗剂的吡唑化合物
ATE519498T1 (de) Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: FOREST LABORATORIES HOLDINGS LIMITED, BM

Free format text: OLD OWNER(S): TROVIS PHARMACEUTICALS LLC

ASS Change of ownership

Owner name: DOGWOOD PHARMACEUTICALS, INC., US

Effective date: 20131003

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 JUN 2014 BY PIPERS

Effective date: 20131111

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 JUN 2017 BY PIPERS

Effective date: 20140416

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2021 BY COMPUTER PACKAGES INC

Effective date: 20200519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210517

ASS Change of ownership

Owner name: ALLERGAN SALES, LLC, US

Effective date: 20210714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2023 BY THOMSON REUTERS

Effective date: 20220502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2024 BY THOMSON REUTERS

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2025 BY THOMSON REUTERS

Effective date: 20240502

LAPS Patent lapsed